Despite Pricing Pressure, Humira Performing Strongly Across Most Metrics, Abbvie Says

Humira continues its strong growth pace through volume gains and market share across therapeutic categories, CEO Gonzalez says, while leukemia drug Imbruvica also had a solid third quarter.